Download pdf
Analysis and research progress on the anticancer effects of Scutellaria barbata
- 1 Alcanta International College, Guangzhou, China
* Author to whom correspondence should be addressed.
Abstract
The most common anti-cancer therapy is to use chemotherapy drugs, but this drug has huge side effects on the patient's body, so some doctors want to study whether there are other natural drugs that can fight cancer and have fewer side effects. And Scutellaria barbata is one of the natural drugs studied by doctors. Scutellaria barbata is often used in traditional Chinese medicine to assist in inhibiting the growth of cancer cells, hoping to reduce the harm of cancer cells to patients. In the database, current doctors have "dissected" the effective ingredients of Scutellaria barbata into five categories. This article analyzes three of them, including flavonoids, polysaccharides and alkaloids. This article analyzes the research on Scutellaria barbata in anti-cancer, and obtained many clinically effective case results and some proven effective ingredients. This article can provide some useful references for future research ideas, but there is still a research gap on how to extract the effective anti-cancer ingredients of Scutellaria barbata and study drugs that can effectively inhibit cancer. Future research can focus on the direction of chemical components of Scutellaria barbata.
Keywords
Scutellaria barbata, alkaloids, anticancer effects, flavonoids
[1]. Ren, S., He, K., Girshick, R., & Sun, J. (2015). Faster R-CNN: Towards real-time object detection with region proposal networks. Advances in neural information processing systems, 28.
[2]. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians.
[3]. Zhu, X. Q., Zheng, Y., Liu, Z. Q., & Wang, B. L. (2020). Network pharmacology analysis of anticancer synergistic mechanism of main flavonoids in Scutellaria barbata. Chinese Journal of Experimental Traditional Medical Formulae, 26(17), 185-191.
[4]. Yu, L. Y., & Bao, Y. (2018). Research progress on the antitumor mechanism of scutellarin. Chinese Journal of Clinical Pharmacy, 27(6), 440-443.
[5]. Chen, R., & Shi, Y. H. (2021). Effect of apigenin on proliferation and apoptosis of endometrial cancer HEC-1-B cells and its mechanism. Tianjin Medical Journal, 49(11).
[6]. Wang, W. H., Li, Z. H., Han, C., Wang, Y., & Xu, R. R. (2024). Research progress on the mechanism of luteolin against lung cancer. Modern Traditional Chinese Medicine. Retrieved from https://link.cnki.net/urlid/61.1397.R.20240709.1656.01. Published online on July 12, 2024.
[7]. Liu, G. Y., Wang, Q., & Su, L. (2023). Research progress on the mechanism of polysaccharide components in anti-pancreatic cancer. Chinese Pharmaceutical Journal, 58(1), 111-116.
[8]. Su, F. Z., Sun, Y. P., Yang, B. Y., & Kuang, H. X. (2021). Research progress on polysaccharides from Scutellaria barbata. Chemical Research and Application. Published on February 6, 2021.
[9]. Li, S. T. (2023). Chemical constituents and anti-inflammatory activity of Scutellaria barbata. (Master’s thesis, Wuyi University). Advisor: Ma Yanyan (Associate Professor), Liu Hongliang. Medicine and Health Science, Traditional Chinese Medicine. Materials and Chemical Engineering. College of Biotechnology and Health. Defense date: May 15, 2023.
[10]. Liu, X., Yan, X. H., Chen, Z. Q., Mei, L., & Fang, Z. F. (2023). Studies on the separation of total alkaloids from Scutellaria barbata and its antitumor activities. Strait Pharmaceutical Journal, 35(4), 12-16.
[11]. Hao, X. S., Feng, P. P., Zhang, Y. Y., & Fei, H. R. (2022). Scutebarbatine B suppresses proliferation and induces apoptosis of human glioma U251 cells. Chinese Journal of Pathophysiology, 38(6), 1001-1007.
[12]. Li, G. X., Fang, Y. H., & Wu, B. (2021). Inhibitory effect of scutebarbatine on the proliferation, migration and invasion of human osteosarcoma cells and its mechanism. Journal of Southeast University (Medical Science Edition), 40(4), 456-462.
[13]. Xia, N., Chen, Y., Wang, G., et al. (2023). Luo Yi's experience in treating gastric cancer from the perspective of spleen deficiency. Hunan Journal of Traditional Chinese Medicine, 39(9), 54-57.
[14]. Yang, Y., & Wang, X. (2017). Examples of Wang Xiaomin's characteristic drug pairs for treating cancer. Liaoning Journal of Traditional Chinese Medicine, 44(9), 1833-1835.
[15]. Zhang, L., Li, L., & Liu, W. (2019). Liu Weisheng's experience in using Scutellaria barbata and Hedyotis diffusa to treat malignant tumors. Liaoning Journal of Traditional Chinese Medicine, 46(10), 2051-2053.
Cite this article
Huang,F. (2024). Analysis and research progress on the anticancer effects of Scutellaria barbata. Theoretical and Natural Science,70,7-12.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).